|
Post by brentie on Sept 26, 2016 8:25:13 GMT -5
|
|
|
Post by otherottawaguy on Sept 26, 2016 9:47:10 GMT -5
Seen this in print more than once now:
"Following the terminated partnership with Sanofi, MannKind has relaunched its ultra-rapid-acting inhaled (needle free) mealtime insulin, Afrezza"
Is this done as a foreshadow to the upcoming label change?
OOG
|
|